Latest news with #SeanTucker
Yahoo
22-06-2025
- Sport
- Yahoo
Buccaneers' Second-Year Running Back Bucky Irving Not Content with Rookie Campaign
Buccaneers' Second-Year Running Back Bucky Irving Not Content with Rookie Campaign originally appeared on Athlon Sports. Tampa Bay Buccaneers running back Bucky Irving brought new life to a very dead rushing attack last season. Advertisement In 2024, alongside then-new offensive coordinator, Liam Coen, Irving helped improve a Bucs running game from one of the worst in the league to a top-five unit. The three-headed monster of Rachaad White, Irving and Sean Tucker led a massively improved rushing game that helped the team to a record-tying fourth straight NFC South division title. Irving began the season splitting time with White, but quickly took over the majority of the carries. But he's not content with that effort and is ready to improve next season. 'I feel like once you always start something new, it's going to have to slow down for you a little bit,' Irving told 'When I first got thrown in, the game was moving pretty fast for me but yeah, as I just settled down and let the game – and just think about it like, 'it's just football.' And not think about too many other things that are going on out there. But yeah, just always going back and looking at the film and looking at things that you can get better at and improve in and also not getting satisfied and stuck in last year, because it's a new year. Nobody cares about what you did last year. Advertisement "It's, 'What can you do for me now?' But I've always been that guy that pretty much never gets stuck in the past ... and work hard every day.' Related: Buccaneers' Mike Evans Credits Baker Mayfield For His Return Related: Mike Florio Hints at a 'Bill Belichick to Tampa Bay Buccaneers' Scenario This story was originally reported by Athlon Sports on Jun 20, 2025, where it first appeared.
The Hill
17-06-2025
- Automotive
- The Hill
New ranking reveals the most American-made cars for 2025
(NEXSTAR) – While it isn't possible to buy a car that is 100% made in the U.S., a new ranking from breaks down the most – and least – American-manufactured cars in 2025. While the site has compiled its America-Made Index for more than a decade, President Trump's announcement of tariffs on foreign-made vehicles has created keen interest in just how 'American' a car is. The analysis assigned scores based on five factors: percentage of U.S. and Canadian parts, location of final assembly, country of origins for available engines, U.S. manufacturing workforce and country of origin for available transmissions. 'Being on this list is crucial as the auto industry becomes more and more global and consumers' desire to use their dollars to support their neighbors increases,' the report states. 'No matter where a vehicle ranks, simply being on the list means it has some component of final assembly in the U.S., ultimately still contributing to the U.S. economy.' At the top of the ranking was the Model 3 by Tesla, which has factories in California and Texas, among other sites. At the bottom of the ranking, in 99th place, was the Toyota RAV4 Hybrid, which fell from the 65th spot in the 2024 ranking. The top 20 most-American cars, according to are: See the full list on the site. Despite President Trump's 25% tariffs on imported cars and parts, the widely-feared spike in car lot prices has not yet materialized. Car shoppers paid $48,799 on average in May, which was $12 less than in April, according to Kelley Blue Book (KBB). Experts don't expect that trend to last, however. 'Price hikes are coming slowly in part because many dealerships keep months' worth of new vehicles in stock, so they still have cars to sell that they imported at pre-tariff prices,' according to KBB reporter Sean Tucker. Tucker wrote that Trump's tariff announcement prompted a flood of early car sales as buyers tried to snatch up the vehicles already on lots in the U.S., but that wave of sales has ended. Discounts offered by major automakers are also starting to fall off. So if the tariffs remain in place, experts suggest that now may still be a good time to buy a car. 'So far there's a mismatch between the expectation of what would happen, and the reality of what has happened with prices,' Ivan Drury, director of insights at told CNN. 'But I still think we're still going to prices start to take off in two to three months.'
USA Today
05-06-2025
- Automotive
- USA Today
Tesla resale prices tumbling. These popular cars hold their value better
Though it's common knowledge that all vehicles lose value, it's not so easy to predict just how much or how quickly your new car or truck will depreciate as you drive it off the lot. For that reason, we turned to experts from Kelley Blue Book/Autotrader and CarGurus for advice about making one of life's biggest purchases – whether it be new or used. "I encourage people not to think of cars as assets because they are not an appreciating thing," said Sean Tucker, lead editor with Kelley Blue Book and Autotrader. "But it is still a major investment, and so there's a reason you don't want to buy the one that has lost 41% of its value in two years." That vehicle, according to Kelley Blue Book data, is the 2023 Tesla Model Y Long Range. "Our industry has never seen anything like what's happened to Tesla over the last year," Tucker said. As CEO Elon Musk worked with President Donald Trump's administration, Tesla saw the lowest Q1 results in three years. "We just don't have a frame of reference for what happens to the value of a car when people start protesting outside the dealerships that sell it," Tucker said. Tesla's Cybertruck stands alone Regardless of which data you review, the 2024 Cybertruck Cyberbeast 4WD has seen a notable drop: ◾ CarGurus provided an average monthly list price (aka the asking price) for the 2024 model year on its website. Below, see how the gray line trends down as the list price fell from $152,571 in May 2024 to $83,062 in May 2025, a 45.6% decrease. ◾ Kelley Blue Book (KBB), an auto valuation company, provided different metrics: two data points, the average manufacture's suggested retail price (MSRP) compared with KBB fair price today (orange line). "The fair price takes into account recent transactions within 50 miles of you within the last week and is constantly updated by what people are currently paying where you live," Tucker said. Based on the national average KBB provided to USA TODAY, a Cybertruck purchased new in May 2024 would fetch about $30,000 less one year later, a 29.4% decrease. Kevin Roberts, director of economic and market intelligence at CarGurus, cautions that the Cybertruck decline needs some context: "While Cybertruck's prices in general look stark, there are a couple of things to keep in mind. When they first were offered in November 2023, it was a really limited volume. That limited supply leads to a lot of consumer interest. And then now we've seen supply is much more normalized. In fact, you're hearing that they have too much inventory in the new side, which puts downward pressure on the price." Can't see our graphics? Click here. How popular car models depreciate over time Kelley Blue Book provided us with the same data points: the average MSRP compared with KBB fair price today for a number of popular 2023 models. Here's what we found: Trucks "Toyota is known for its high-end, predictable quality. They just keep their value better," Tucker said. Also, high resale value might be why you want to buy a Tacoma, Tucker said. For the F-150, Tucker notes the EV Lightning model had an even larger decrease. "Ford did everything it could to make those trucks functionally identical," Tucker said. "With new technology, a new market, there's always a threat that we don't face with gas-powered cars, which is that the technology could change drastically in the next few years." Midsize and crossover SUVs The popular Jeep Grand Cherokee saw a 31.3% decline over the past two years. "I think generally I would rather own a 3-year old Subaru than a 3-year old Jeep," Tucker said. "Jeep is a Stellantis brand, and they have kind of struggled with their long-term quality. I think it's improving, but that has been the perception for a long time." The real standout in the midsize/crossover category is the Hyundai Palisade and its 10-year powertrain warranty, Tucker said. "If you own a 2-year-old palisade, you have eight years left of warranty protection, which is just not the case with either of the other cars in there." Compact SUVs The 2023 Tesla Model Y Long Range saw a 41.1% drop when comparing the KKB fair price in 2023 with the average MSRP. "That comes down to what's happened to Tesla over the past year or even really the past six months," Tucker said. Sedans The Honda Accord dropped by 17.8%, or roughly $5,500. "Honda, very similar to Toyota, has that strong reliability reputation. These things last forever, and it shows up when it comes time to resell it," Tucker said. Vehicles that saw the biggest and smallest changes in used listing prices CarGurus looked at used 2024 models listed on its site from May 2024 through May 2025. From all vehicles available, it chose the five vehicles that declined the most in listing price and the five that declined the least. What they found: The five models from CarGuru's data with the biggest drop in list price from May 2024 to May 2025: Tesla Cybertruck: Down $69,509, 45.6% ($152,571 - $83,062) Down $69,509, 45.6% ($152,571 - $83,062) Ford F-150: Down $34,833, 37.7% ($92,502 - $57,669) Down $34,833, 37.7% ($92,502 - $57,669) RAM 1500: Down $16,279, 25.6% ($63,592 - $47,314) Down $16,279, 25.6% ($63,592 - $47,314) Range Rover : Down $43,293, 24.7% ($175,187 - $131,894) : Down $43,293, 24.7% ($175,187 - $131,894) Jeep Wrangler: Down $15,451, 24.2% ($63,940 - $48,488) Cybertruck: When looking at the decline in Tesla's Cybertruck price, the difference can be jaw-dropping. The Cybertruck saw a 45.6%, $69,509, price drop from May 2024 to May 2025. Roberts believes the initial price of the Cybertruck was probably artificially high. "There's even people I think at time were trying to flip them," Roberts said. "That drove the average list price higher than what the market would have been." Ford F-150, Jeep Wrangler: These models fell victim to an oversupply in the new market because of the 2021-2022 microchip shortage, Roberts said. "2024 is where we really started to see new inventory levels start to recover. And for certain brands, they got way too much inventory. With potential incentives on the new side, that puts more downward pressure on the used side price." Land Rover, Range Rover: "Known for its luxury styling and features, but typical of many premium brands, is likely experiencing steeper early price depreciation," Roberts said. Ram 1500: "This represents the final year of the previous generation," Roberts said, "with the all-new 2025 model likely effecting used pricing dynamics." The five models from CarGuru's data that declined the least or are up from May 2024 to May 2025: Subaru Crosstrek: Down $36, 0.1% ($29,690 - $29,654) Down $36, 0.1% ($29,690 - $29,654) Subaru Forester: Down $91, 0.3% ($33,693 - $33,602) Down $91, 0.3% ($33,693 - $33,602) Porsche Cayenne : Down $1,082, 1.1% ($102,637 - $101,555) Down $1,082, 1.1% ($102,637 - $101,555) Toyota RAV4 Hybrid: Down $596, 1.6% ($37,698 - $37,102) Down $596, 1.6% ($37,698 - $37,102) Porsche Macan: Down $1,342, 1.9% ($70,006 - $68,664) Subaru: "Subaru is in a situation where they have a lot tighter inventory, particularly for some of those kind of popular CUVs," Roberts said. "That leads to a situation where, hey, maybe you want a certain model, you might have an easier time on the used market, which helps to kind of prop up those prices." Porsche: "Luxury can be different," Roberts said. "You see a couple Porsches on the lis;, there's a limited supply in the marketplace and a lot of demand. That can lead to prices actually moving up on some of the used units." Toyota RAV4 Hybrid: "Much like the Subarus, the RAV4 continues to face some of the tightest supply in the market," Roberts said.
Yahoo
02-06-2025
- Business
- Yahoo
Vaxart Announces Adjournment of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company') announced today that its 2025 annual meeting of stockholders (the 'Annual Meeting') has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 10, 2025 (the 'Proxy Statement'). 'In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,' said Steven Lo, Chief Executive Officer of Vaxart. 'I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.' The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. Proxies previously submitted with respect to the Annual Meeting will be voted on all applicable proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Both leading independent proxy advisory firms, Institutional Shareholder Services ('ISS') and Glass Lewis, recommend that stockholders support Proposal No. 2. A message from Dr. Sean Tucker, Founder and Chief Scientific Officer, and a fact sheet that addresses several misconceptions about the proposed reverse stock split can be found on Vaxart's investor relations website at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as the annual meeting of stockholders, our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@ 871-8481 This press release was published by a CLEAR® Verified in to access your portfolio
Globe and Mail
29-05-2025
- Business
- Globe and Mail
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the 'Company' OR 'Vaxart') today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compliance with Nasdaq's minimum bid price rule. Additionally, to ensure stockholders have accurate information as they consider this important proposal, the Company addresses several misconceptions in the attached fact sheet: A PDF accompanying this announcement is available at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLC Toll-Free: 1-855-264-1527 Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, financial performance and condition, and regaining compliance with the Nasdaq minimum bid price requirement. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the Solicitation The Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at This press release was published by a CLEAR® Verified individual.
